Acadia Pharmaceuticals Inc. announced top-line results from the Phase III ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia
Gilead Sciences, Inc. and Evoq Therapeutics, Inc. announced a collaboration and licensing agreement to advance Evoq’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus
Protagonist Therapeutics, Inc. announced two additional Phase III studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ 2113 (formerly PN 235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis
The OraQuick Advance Rapid HIV-112 Antibody Test, from OraSure, is comparable in accuracy to the traditional blood test, according to...
AbbVie announced positive results from two Phase III induction studies, ADVANCE and MOTIVATE, showing both doses of Skyrizi (risankizumab) (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn's disease.
Takeda announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase III clinical trial evaluating HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.
Biogen Idec released the primary efficacy analysis and safety data from its Phase III pivotal clinical trial, ADVANCE. Results support...
Horizon Therapeutics plc announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of Krystexxa (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with Krystexxa monotherapy.
Spectrum Pharmaceuticals, Inc. announced detailed results from ADVANCE, a Phase III trial of Rolontis demonstrating that it was non-inferior to...